{"nctId":"NCT01515657","briefTitle":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients","startDateStruct":{"date":"2012-01"},"conditions":["Diabetes Mellitus, Type 2"],"count":40,"armGroups":[{"label":"PL2200 Aspirin Capsules","type":"EXPERIMENTAL","interventionNames":["Drug: PL2200 Aspirin Capsules"]},{"label":"Immediate-Release Aspirin Tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Immediate-Release Aspirin Tablets"]},{"label":"Enteric-coated aspirin caplets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enteric-coated aspirin caplets"]}],"interventions":[{"name":"PL2200 Aspirin Capsules","otherNames":[]},{"name":"Immediate-Release Aspirin Tablets","otherNames":[]},{"name":"Enteric-coated aspirin caplets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults 21-79\n* Body mass index (BMI) of 30-40 kg/m2\n* Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of \\> 6.4% and/or fasting plasma glucose of \\>125 mg/dL or current anti-diabetic medication)\n* AA-induced platelet aggregation response of \\>60% within 3 hours prior to initial dose of study drug administration\n\nExclusion Criteria:\n\n* Contraindications to aspirin\n* Previous history of vascular disease\n* Patient requires insulin\n* Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to 99% Inhibition of Serum Thromboxane (TxB2)","description":"Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.36","spread":"23.42"},{"groupId":"OG001","value":"16.65","spread":"27.21"},{"groupId":"OG002","value":"48.64","spread":"31.20"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":["Nausea","Headache","Viral Infection","Dizziness"]}}}